BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/27/2024 11:58:45 AM | Browse: 497 | Download: 1317
Publication Name World Journal of Hepatology
Manuscript ID 89977
Country Italy
ISSN 1948-5182 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Editorial
Article Title Can rifaximin for hepatic encephalopathy be discontinued during broad-spectrum antibiotic treatment?
Manuscript Source Invited Manuscript
All Author List Chien-Hao Huang and Piero Amodio
ORCID
Author(s) ORCID Number
Chien-Hao Huang http://orcid.org/0000-0003-1689-3221
Piero Amodio http://orcid.org/0000-0002-2395-7599
Funding Agency and Grant Number
Funding Agency Grant Number
the Chang Gung Medical Research Project CMRPG3M1931-1932
the National Science and Technology Council MOST 110-2314-B-182A-093- and NMRPG3L0331
Corresponding Author Piero Amodio, Doctor, MD, Academic Editor, Additional Professor, Department of Clinical and Experimental Medicine, University of Padua, Via Giustiniani, 2, Padova 35122, Italy. piero.amodio@unipd.it
Key Words Rifaximin discontinuation; Hepatic encephalopathy; Broad-spectrum antibiotics; Crit-ically ill; Medical intensive care unit; Pharmacist-driven protocol
Core Tip Rifaximin (RFX) is a gut-restricted adjunct to lactulose that minimizes hepatic encephalopathy (HE) recurrence with minimal systemic absorption. Despite established benefits, limited Food and Drug Administration approval for acute HE raises concern about its use in treating acute overt HE. Recent evidence challenges the routine use of RFX with broad-spectrum antibiotics, emphasizing their class-specific effects in critically ill patients. The study sheds light on the safety of discontinuing RFX during broad-spectrum antibiotic therapy in intensive care unit patients with liver disease and HE, and also prompts reevaluation of the role of RFX amid the overlapping antibiotic activity. This evidence underscores the need for further investigations to optimize the management of both HE and systemic infections in patients with liver disease, including those who are not critically ill.
Publish Date 2024-02-27 11:58
Citation Huang CH, Amodio P. Can rifaximin for hepatic encephalopathy be discontinued during broad-spectrum antibiotic treatment? World J Hepatol 2024; 16(2): 115-119
URL https://www.wjgnet.com/1948-5182/full/v16/i2/115.htm
DOI https://dx.doi.org/10.4254/wjh.v16.i2.115
Full Article (PDF) WJH-16-115-with-cover.pdf
Full Article (Word) WJH-16-115.docx